Patent
Methods for modulating signal transduction mediated by TGF-β and related proteins
| العنوان: | Methods for modulating signal transduction mediated by TGF-β and related proteins |
|---|---|
| Patent Number: | 7,358,056 |
| تاريخ النشر: | April 15, 2008 |
| Appl. No: | 09/385918 |
| Application Filed: | August 30, 1999 |
| مستخلص: | Methods are provided for identifying agents that modulate signaling mediated by transforming growth factor beta (TGF-β) and members of the TGF-β family, such as bone morphogenic protein (BMP). Such agents may be identified using screens that evaluate candidate agents for the ability to modulate Smad protein degradation. Agents identified as described herein may be used to augment or inhibit signaling mediated by one or more TGF-β family members in a variety of cell types and for therapeutic purposes. |
| Inventors: | Hoekstra, Merl F. (Cardiff-by-the-sea, CA, US); Xie, Weilin (San Diego, CA, US); Murray, Brion W. (San Diego, CA, US); Mercurio, Frank M. (Del Mar, CA, US) |
| Assignees: | Signal Pharmaceuticals (San Diego, CA, US) |
| Claim: | 1. A method for screening for an agent that modulates BMP-mediated signaling, comprising: (a) contacting (i) a HECT E3 ubiquitin ligase WW domain, wherein the domain comprises SEQ ID NOS:1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or 13; (ii) a Smad PY motif, wherein the motif comprises SEQ ID NOS: 14, 15, 16, 17, 20, 21, 22, 23, 24, or 25; and (iii) a candidate agent; under conditions that permit a detectable level of binding of the HECT E3 ubiquitin ligase WW domain to the Smad PY motif in the absence of the candidate agent; and (b) comparing the level of binding of the HECT E3 ubiquitin ligate WW domain to the Smad PY motif in the presence of the candidate agent to a control level of binding of the HECT E3 ubiquitin ligase WW domain to the Smad PY motif in the absence of candidate agent, and therefrom determining whether the candidate agent modulates BMP-mediated signaling. |
| Claim: | 2. The method according to claim 1 , wherein the HECT E3 ubiquitin ligase WW domain comprises the sequence: Gly-Pro-Leu-Pro-Xaa-Gly-Trp-Glu-Xaa-Xaa-Xaa-Taa-Taa-Gly-Taa-Xaa-Tyr-Tyr-Haa-Xaa-His-Asn-Thr-Taa-Thr-Thr-Taa-Trp-Xaa-Taa-Pro-Taa (SEQ ID NO:2); wherein each Taa is an independently selected polar amino acid residue, Haa is a hydrophobic residue and each Xaa is an independently selected amino acid residue. |
| Claim: | 3. The method according to claim 1 , wherein the Smad PY motif comprises the sequence Ser/Thr-Pro-Pro-Pro-Pro/Ala/Gly-Tyr (SEQ ID NO:15), wherein Ser/Thr is an amino acid residue that is serine or threonine and Pro/Ala/Gly is an amino acid residue that is selected from the group consisting of proline, alanine, and glycine. |
| Claim: | 4. The method according to claim 3 , wherein the Smad PY motif comprises the sequence Thr-Pro-Pro-Pro-Ala-Tyr (SEQ ID NO:16), Thr-Pro-Pro-Pro-Gly-Tyr (SEQ ID NO:18) or Pro-Ala-Asp-Thr-Pro-Pro-Pro-Ala-Tyr-Leu/Met-Pro-Pro-Pro-Asp (SEQ ID NO:17), wherein Leu/Met is an amino acid residue that is leucine or threonine. |
| Claim: | 5. The method according to claim 1 , wherein the candidate agent is a small molecule within a combinatorial library. |
| Claim: | 6. The method according to claim 1 , wherein the HECT E3 ubiquitin ligase WW domain is immobilized on a solid support and the Smad PY motif comprises a tag. |
| Claim: | 7. The method according to claim 1 , wherein the Smad PY motif is immobilized on a solid support and the HECT E3 ubiquitin ligase WW domain comprises a tag. |
| Claim: | 8. The method according to claim 6 or claim 7 , wherein the tag is biotin or a radioactive group. |
| Claim: | 9. The method according to claim 1 , wherein the level of binding is determined via a two-antibody sandwich assay. |
| Claim: | 10. The method according to claim 1 , wherein the level of binding is determined via a competitive assay. |
| Claim: | 11. The method according to claim 2 , wherein each Taa is selected from the amino acid residue group consisting of Ser, His, Pro, Asp, Glu, Thr, and Tyr. |
| Claim: | 12. The method according to claim 2 , wherein each Haa is selected from the hydrophobic residue group consisting of Ile, Val, Leu, and Met. |
| Claim: | 13. The method of claim 1 , wherein: (i) when the level of binding of the HECT E3 ubiquitin ligase WW domain to the Smad PY motif is increased as compared to the control level, the agent decreases BMP-mediated signaling, or (ii) when the level of binding of the HECT E3 ubiquitin ligase WW domain to the Smad PY motif is decreased as compared to the control level, the agent increases BMP-mediated signaling. |
| Claim: | 14. The method of claim 1 , wherein said determining whether the candidate agent modulates BMP-mediated signaling further comprises the step of measuring or otherwise determining the level of Smad ubiquitination in the presence of the agent as compared to in the absence of the agent, wherein: (i) an increase in Smad ubiquitination indicates the agent decreases BMP-mediated signaling, or (ii) a decrease in Smad ubiquitination indicates the agent increases BMP-mediated signaling. |
| Claim: | 15. The method of claim 1 , wherein said determining whether the candidate agent modulates BMP-mediated signaling further comprises the step of measuring or otherwise determining the level of Smad protein in the presence of the agent as compared to in the absence of the agent, wherein: (i) an increase in Smad protein indicates the agent increases BMP-mediated signaling, and (ii) a decrease in Smad protein indicates the agent decreases BMP-mediated signaling. |
| Claim: | 16. The method of claim 1 , wherein said HECT E3 ubiquitin ligase WW domain consists of the amino acid sequence of SEQ ID NOS:1, 2, 3, 4, 5, 6 7, 8, 9, 10, 11, 12, or 13. |
| Claim: | 17. The method of claim 1 , wherein said Smad PY motif consists of SEQ ID NOS:14, 15, 16, 17, 20, 21, 22, 23, 24, or 25. |
| Claim: | 18. The method of claim 1 , wherein said HECT E3 ubiquitin ligase WW domain consists of the amino acid sequence of SEQ ID NO:1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or 13; and wherein said Smad PY motif consists of SEQ ID NOS:14, 15, 16, 17, 20, 21, 22, 23, 24, or 25. |
| Current U.S. Class: | 435/72 |
| Patent References Cited: | 6001619 December 1999 Beach et al. 6011137 January 2000 Pirozzi et al. 6060262 May 2000 Beer-Romero et al. 6087122 July 2000 Husted et al. 6103869 August 2000 Souchelnytokyi et al. WO 99/01765 January 1999 WO 00/77168 December 2000 |
| Other References: | Zhu et al., A SMAD ubiquitin ligase targets the BMP pathway and affects embryonic differentiation. 1999, Nature vol. 400, pp. 687-693. cited by examiner Guo et al., PNAS, vol. 101, No. 25, pp. 9205-9210, 2004. cited by examiner Wells, Biochemistry, vol. 29, pp. 8509-8517, 1990. cited by examiner Attisano et al., 1993, “Identification of human activin and TGF beta type I receptors that form heteromeric kinase complexes with type II receptors”, Cell 75(4):671-80. cited by other Attisano et al., 1996, “Activation of signalling by the activin receptor complex”, Mol Cell Biol. 16(3):1066-73. cited by other Cui et al., 1996, “TGFbeta1 inhibits the formation of benign skin tumors, but enhances progression to invasive spindle carcinomas in transgenic mice”, Cell 86(4):531-42. cited by other Derynck, 1998, “Smads: transcriptional activators of TGF-beta responses”, Cell 95(6):737-40. R. cited by other Hayashi et al., 1997, “The MAD-related protein Smad7 associates with the TGFbeta receptor and functions as an antagonist of TGFbeta signaling”, Cell 89(7):1165-73. cited by other Heldin et al., 1997, “TGF-beta signalling from cell membrane to nucleus through SMAD proteins”, Nature 390: 465-471. cited by other Hershko et al., 1983, “Components of ubiquitin-protein ligase system. Resolution, affinity purification, and role in protein breakdown”, J Biol Chem. 258(13):8206-14. cited by other Hojo et al., 1999, “Cyclosporine induces cancer progression by a cell-autonomous mechanism”, Nature 397(6719):530-4. cited by other Huibregtse et al., 1995, A family of proteins structurally and functionally related to the E6-AP ubiquitin-protein ligase. Proc Natl Acad Sci U S A. 92(7):2563-7. cited by other Huibregtse et al., 1993, “Cloning and expression of the cDNA for E6-AP, a protein that mediates the interaction of the human papillomavirus E6 oncoprotein with p53”, Mol Cell Biol. 13(2):775-84. cited by other Imamura, 1997, “Smad6 inhibits signalling by the TGF-beta superfamily”, Nature 389(6651):622-6. cited by other Kretzschmar et al., 1997, “Opposing BMP and EGF signalling pathways converge on the TGF-beta family mediator Smad1”, Nature 389(6651):618-22. cited by other Kretzschmar and Massague, 1998, “SMADs: mediators and regulators of TGF-beta signaling”, Curr Opin Genet Dev. 8(1):103-11. cited by other Lin et al., 1992, “Expression cloning of the TGF-beta type II receptor, a functional transmembrane serine/threonine kinase”, Cell 68(4):775-85. cited by other Liu et al., 1996, “A human Mad protein acting as a BMP-regulated transcriptional activator”, Nature 381(6583):620-3. cited by other Markowitz et al., 1995, “Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability”, Science 268(5215):1336-8. cited by other Mathews and Vale, 1991, “Expression cloning of an activin receptor, a predicted transmembrane serine kinase”, Cell. 65(6):973-82. cited by other Miyazono et al., 1999, “Signal transduction by bone morphogenetic protein receptors”, Bone 25(1): 91-93. cited by other Nakao et al., 1997, “Identification of Smad2, a human Mad-related protein in the transforming growth factor beta signaling pathway”, J Biol Chem. 272(5):2896-900. cited by other Newfeld et al., 1996, “Mothers against dpp encodes a conserved cytoplasmic protein required in DPP/TGF-beta responsive cells”, Development 122(7):2099-108. cited by other Pirozzi et al., 1997, “Identification of novel human WW domain-containing proteins by cloning of ligand targets”, J Biol Chem. 272(23):14611-6. cited by other Reynisdottir et al., 1995, Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-beta. Genes Dev. 9(15):1831-45. cited by other Sekelsky et al., 1995, “Genetic characterization and cloning of mothers against dpp, a gene required for decapentaplegic function in Drosophila melanogaster”, Genetics 139(3):1347-58. cited by other Staub et al., 1996, “WW domains of Nedd4 bind to the proline-rich PY motifs in the epithelial Na+ channel deleted in Liddle's syndrome”, EMBO J. 15(10):2371-80. cited by other Sudol et al., 1996, “Structure and function of the WW domain”, Prog Biophys Mol Biol. 5(1-2):113-32. cited by other Tsuchida et al., 1993, “Cloning and characterization of a transmembrane serine kinase that acts as an activin type I receptor”, Proc Natl Acad Sci U S A. 90(23):11242-6. cited by other Ulloa et al., 1999, Inhibition of transforming growth factor-beta/SMAD signalling by the interferon-gamma/STAT pathway. Nature 397(6721):710-3. cited by other Zawel et al., 1998, “Human Smad3 and Smad4 are sequence-specific transcription activators”, Mol Cell. 1(4):611-7. cited by other Zhang et al., 1996, “Receptor-associated Mad homologues synergize as effectors of the TGF-beta response”, Nature 383(6596):168-72. cited by other Zhu et al., 1998, “Smad3 mutant mice develop metastatic colorectal cancer”, Cell 94(6):703-14. cited by other Zhu et al., 1999, “A SMAD ubiquitin ligase targets the BMP pathway and affects embryonic pattern formation”, Nature 400: 687-93. cited by other Wrana et al., 2000, “The Smad pathway,” Cytokine & Growth Factor Reviews 11:5-13. cited by other |
| Primary Examiner: | Robinson, Hope |
| Attorney, Agent or Firm: | Jones Day |
| رقم الانضمام: | edspgr.07358056 |
| قاعدة البيانات: | USPTO Patent Grants |
| الوصف غير متاح. |